The letter of intent is not a handshake. It is a document that sets the terms, tone, and trajectory of your entire transaction. Most sellers treat it as a preliminary step, a starting point before the real negotiation begins. That assumption is expensive. The moment you sign an LOI, your leverage shifts. Buyers know it. Their advisors count on it. What you agree to, and what you leave unaddressed, before that signature determines how much value you walk away with.
This article breaks down the key terms you need to evaluate, negotiate, and protect before signing a healthcare LOI, so you enter the deal with your eyes open and your position intact.
What a Healthcare LOI Actually Commits You To
LOIs are often described as non-binding, but that framing is misleading. While the purchase price and final terms may not be legally enforceable at this stage, several provisions typically are binding, including exclusivity, confidentiality, and sometimes break-up fee structures. Sellers who treat the entire document as a formality miss this distinction.
The LOI also carries significant practical weight beyond its binding provisions. Buyers and their legal teams use LOI language as the baseline when drafting the definitive purchase agreement. Terms that seem vague or seller-friendly in the LOI tend to become more detailed and buyer-friendly in the final document. If you did not define something clearly up front, you will negotiate it later from a weaker position.
Purchase Price and Deal Structure: More Than a Number
The headline number rarely tells the full picture. Most healthcare deals involve some combination of cash at close, earnout provisions, and equity rollover into the acquiring entity. Each component carries a different level of risk for you as the seller, and the mix matters as much as the total.
Earnout provisions deserve particular scrutiny. Buyers often tie a portion of the purchase price to future performance metrics, revenue thresholds, or EBITDA targets. Push for clear definitions, measurable benchmarks, and protections against post-close operational changes that could affect your ability to hit those targets. A poorly defined earnout is a deferred reduction in your payout.
Working capital adjustments are another area where sellers give up value without realizing it. If the LOI does not define the working capital target and the methodology for calculating it, you may face a post-close adjustment that quietly reduces what you receive at the table. Resolve that framework now, not during final negotiations when your options are narrower.
Exclusivity and the “No-Shop” Clause: What You’re Giving Up
When you agree to exclusivity, you agree to stop talking to other buyers. That is a real concession and should be treated as one. Typical exclusivity periods in healthcare transactions run 60 to 90 days, but buyers frequently request longer windows, especially when they anticipate a complex due diligence process.
Negotiate the duration and termination rights. If the buyer misses key milestones, such as completing due diligence, delivering a draft purchase agreement, or securing financing commitments, you should have a defined path to exit exclusivity and re-engage the market. Without those protections, a buyer can use the exclusivity period to slow-walk the process, wear down your team, and renegotiate terms after your alternatives have gone cold.
Due Diligence Scope and Timeline: Setting Boundaries Early
Buyers will request broad access during due diligence, and some of those requests are reasonable. Others are overreaching. At the LOI stage, you can define what access looks like, what data rooms will contain, and what requires additional approval before disclosure.
In healthcare transactions, this matters more than in most industries. Patient data, payer contracts, provider credentialing files, and compliance documentation are all sensitive. You need clear boundaries around what gets shared, when, and with whom, particularly if the deal does not close. Tie due diligence timelines to specific milestones and deadlines so the process does not drag on indefinitely while you remain locked out of the market.
Personnel, Leadership, and Post-Close Commitments
If the LOI references your post-close role, read it carefully. Buyers often frame transition expectations loosely at the LOI stage and tighten the language significantly in the definitive agreement. Whether you are expected to stay on for six months or three years, the scope of that commitment should be defined before you sign.
Non-compete and non-solicitation provisions deserve the same attention. These clauses define where you can work, who you can recruit, and how long those restrictions apply. The scope, duration, and geography of a non-compete can meaningfully affect your professional future. Negotiate them now, when you still have leverage, not after the deal closes and your options narrow considerably.
What the LOI Usually Leaves Out and Why That’s a Problem
Representations, warranties, and indemnification exposure rarely appear in an LOI. That does not mean they are not coming. Sellers who do not anticipate these provisions are often caught off guard by the breadth of indemnification obligations in the final agreement, particularly around regulatory compliance, billing practices, and licensing.
Regulatory and licensing transfer is another area that deserves early attention. In healthcare, licenses do not always transfer automatically. If the deal structure requires new licensure, credentialing, or payer enrollment, those timelines affect your close date and your risk exposure. Gaps in the LOI give buyers room to renegotiate after due diligence, using issues they surface as leverage to reduce price or adjust terms.
Who Should Be in the Room Before You Sign
General counsel and transaction-experienced advisors are not interchangeable. A lawyer who handles contracts and employment matters may not have the specific deal experience needed to evaluate LOI terms in the context of a healthcare transaction. The nuances of earnout structures, working capital mechanics, and exclusivity provisions require advisors who have worked through these deals before.
A financial advisor or investment banker with experience in healthcare transactions adds a different layer of value. They can assess whether the deal structure reflects market norms, identify where you are leaving value on the table, and help you prioritize which terms to push on and which to accept. That guidance costs a fraction of what a poorly negotiated LOI can cost you at close.
FAQs
Is a healthcare LOI legally binding?
Most of the LOI is non-binding on price and final terms, but provisions like exclusivity, confidentiality, and break-up fees are typically enforceable the moment you sign.
How long should the exclusivity period in an LOI last?
Healthcare LOIs typically run 60 to 90 days, and you should negotiate termination rights tied to buyer milestones like completing due diligence or delivering a draft purchase agreement.
Why do working capital adjustments matter at the LOI stage?
If the working capital target and calculation methodology are not defined upfront, a post-close adjustment can quietly reduce your final payout without much room to push back later.
Review the LOI Before You Give Up Leverage
A healthcare LOI can lock in more terms than sellers realize. Once exclusivity begins, vague terms around purchase price, earnouts, working capital, diligence, and post-close obligations can quickly become leverage for the buyer. Before you sign, make sure the LOI protects your value, timeline, and future options by connecting with an Inflection 360 expert.
